David E Spaner

List of Publications by Year
in descending order

45 papers	932 citations	430874 18 h-index	477307 29 g-index
45 all docs	45 docs citations	45 times ranked	1481 citing authors

#	Article	IF	Citations
1	Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial. Cancer Medicine, 2021, 10, 8789-8798.	2.8	6
2	O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers. Frontiers in Immunology, 2021, 12, 772304.	4.8	6
3	Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells. Journal of Immunology, 2020, 205, 2629-2639.	0.8	9
4	Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. Leukemia, 2019, 33, 1650-1662.	7.2	10
5	Persistent janus kinaseâ€signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial. Cancer Medicine, 2019, 8, 1540-1550.	2.8	14
6	Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis. Cell Death and Disease, 2019, 10, 117.	6.3	29
7	A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma, 2019, 60, 980-989.	1.3	8
8	Autologous stem cell transplant and combination immunotherapy of rituximab and interferonâ€Î± induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology, 2019, 184, 469-472.	2.5	4
9	An autologous tumor vaccine for CLL. Leukemia Research, 2018, 68, 40-47.	0.8	8
10	Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro. Leukemia Research, 2018, 66, 28-38.	0.8	20
11	Peroxisome Proliferator-Activated Receptorâ€"Î´ Supports the Metabolic Requirements of Cell Growth in TCRÎ²-Selected Thymocytes and Peripheral CD4+ T Cells. Journal of Immunology, 2018, 201, 2664-2682.	0.8	13
12	Novel flavaglineâ€like compounds with potent Fliâ€1 inhibitory activity suppress diverse types of leukemia. FEBS Journal, 2018, 285, 4631-4645.	4.7	22
13	Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia. EBioMedicine, 2018, 35, 222-232.	6.1	7
14	Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells. EBioMedicine, 2017, 15, 24-35.	6.1	36
15	Response. Journal of the National Cancer Institute, 2017, 109, .	6.3	0
16	The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of the National Cancer Institute, 2017, 109, djw226.	6.3	22
17	Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. Oncotarget, 2016, 7, 72608-72621.	1.8	15
18	High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood, 2016, 128, 934-947.	1.4	104

#	Article	IF	Citations
19	Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial. Haematologica, 2016, 101, e192-e195.	3.5	29
20	A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15. Blood, 2016, 128, 4162-4162.	1.4	2
21	Characterization of CD200 Ectodomain Shedding. PLoS ONE, 2016, 11, e0152073.	2.5	16
22	A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-Î± Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo. Molecular Medicine, 2015, 21, 410-419.	4.4	35
23	Inhibition of Dexamethasone-induced Fatty Liver Development by Reducing miR-17-5p Levels. Molecular Therapy, 2015, 23, 1222-1233.	8.2	28
24	Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. Blood, 2015, 126, 766-778.	1.4	41
25	Antagonizing Peroxisome Proliferatorâ€“Activated Receptor Î± Activity Selectively Enhances Th1 Immunity in Male Mice. Journal of Immunology, 2015, 195, 5189-5202.	0.8	30
26	The Association of Dyslipidemia with the Development of Chronic Lymphocytic Leukemia: A Population-Based Study. Blood, 2015, 126, 5268-5268.	1.4	0
27	Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.. Journal of Clinical Oncology, 2014, 32, 3028-3028.	1.6	3
28	PPARÎ± and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood, 2013, 122, 969-980.	1.4	77
29	Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia patients.. Journal of Clinical Oncology, 2012, 30, 10622-10622.	1.6	1
30	Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood, 2011, 117, 2668-2680.	1.4	48
31	Toll-like Receptor-7 Tolerizes Malignant B Cells and Enhances Killing by Cytotoxic Agents. Cancer Research, 2007, 67, 1823-1831.	0.9	57
32	Extracellular calcium sensing promotes human B-cell activation and function. Blood, 2007, 110, 3985-3995.	1.4	26
33	Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity. Journal of Immunology, 2006, 176, 3830-3839.	0.8	47
34	Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.. Blood, 2006, 108, 3051-3051.	1.4	5
35	Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.. Blood, 2006, 108, 3067-3067.	1.4	4
36	Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells. Journal of Immunotherapy, 2005, 28, 28-39.	2.4	20

#	Article	IF	Citations
37	Foreign Body Granuloma: A New Manifestation of Immune Restoration Syndrome. Journal of Cutaneous Medicine and Surgery, 2003, 7, 38-42.	1.2	20
38	Prolonged Molecular and Clinical Remission after Treatment of a Patient with Follicular Lymphoma with Rituximab. Leukemia and Lymphoma, 2001, 41, 451-455.	1.3	5
39	ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but not in tumors arising from mature B-cells. Cancer Immunology, Immunotherapy, 2001, 50, 345-355.	4.2	0
40	Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion. Journal of Cellular Biochemistry, 2000, 77, 569-583.	2.6	43
41	Immunogenicity of Whole-Cell Tumor Preparations Infected with the ALVAC Viral Vector. Human Gene Therapy, 2000, 11, 1289-1301.	2.7	7
42	Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion. Journal of Cellular Biochemistry, 2000, 77, 569.	2.6	1
43	Phosphorylation of p53 protein in response to ionizing radiation occurs at multiple sites in both normal and DNA-PK deficient cells. Oncogene, 1999, 18, 1521-1527.	5.9	22
44	Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies. , 1998, 17, 249-257.		3
45	The scid Mouse: Mutation in a DNA Repair Gene Creates Recipients Useful for Studies on Stem Cells, Lymphocyte Development and Graft-versus-Host Disease. Immunological Reviews, 1991, 124, 63-74.	6.0	29